Print

BELGRADE, Mont., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced preliminary results of its fourth quarter 2015 and preliminary full year results.

Preliminary Consolidated Fourth Quarter 2015 Results

Consolidated revenue for the fourth quarter 2015 was approximately $22.0 to $22.2 million, an increase of 12.7 to 13.8% compared to consolidated pro forma revenue of approximately $19.5 million for the fourth quarter of 2014. During the fourth quarter of 2015, gross margin is expected to be between 66.5% and 68.0% versus 66.5% for the same period in 2014.

Visit Original Source